Browse All

Current Filters

CLEAR FILTER x

TITLE

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease

Author:Giovannoni, Gavin   Airas, Laura   Bove, Riley   Cutter, Gary   Hobart, Jeremy   Kuhle, Jens   Montalban, Xavier   Tur, Carmen   Wolinsky, Jerry   Schneble, Hans-Martin   Baldinotti, Anna   Bonati, Ulrike   Giacobino, Caroline   Wang, Qing   Yang, Ke   Oh, Jiwon   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.001  

Author Institution:Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK and Blizard Institute, Queen Mary University, London, UK, London, United Kingdom  University of Turku, Turku, Finland, Turku, Finland  UCSF Weill Institute for Neuroscience, Department of Neurology, University of California San Francisco, San Francisco, CA, USA, CA  The University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA, Birmingham, AL  Peninsula Medical School, Plymouth University, UK, Plymouth, United Kingdom  MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland, Switzerland  Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Queen Square MS Centre, Department of Neuroinflammation, Institute of Neurology, Faculty of Brain Sciences, University College London (UCL), London, UK/Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (CEMCAT), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, Un  Department of Neurology, University of Texas Health Science Center, Houston, TX, USA, TX  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Switzerland  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada, ON, Canada  

Humoral Vaccine Responses and One-year Follow-up of Infants Potentially Exposed to Ocrelizumab During Pregnancy and Breastfeeding: Final Analyses of the Prospective, Multicenter, Open-label, Phase IV Studies MINORE and SOPRANINO

Author:Dobson, Ruth   Bove, Riley   Hellwig, Kerstin   Oreja-Guevara, Celia   Derfuss, Tobias J.   Shah, Anna   Graham, Edith L.   McElrath, Thomas F.   Pietrasanta, Carlo   Maillart, Elisabeth   Jacobs, Dina   Kazlauskaite, Agne   Alves, Daniela   Raposo, Catarina   Craveiro, Licinio   Lin, Chien-Ju   Pasquarelli, Noemi   Vukusic, Sandra   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.002  

Author Institution:Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK, London, United Kingdom  Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA, Berkeley, CA  Katholisches Klinikum Bochum, St. Josef Hospital, Universitätsklinikum, Bochum, Germany, Bochum, Germany  Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain, Madrid, Spain  University Hospital Basel, University of Basel, Basel, Switzerland, Basel, Switzerland  Rocky Mountain MS Center, Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Multiple Sclerosis and Neuroimmunology, Northwestern University, Chicago, IL, USA, Chicago, IL  Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, MA  NICU, Department of Woman, Child and Newborn, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, Milan, Italy  Neurology Department, Hôpital de la Pitié Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France, Paris, France  Department of Neurology, Perelman School of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Roche Products Ltd, Welwyn Garden City, UK, Welwyn Garden City, United Kingdom  Service de Neurologie et Sclérose en Plaques, Fondation Eugène Devic EDMUS contre la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Lyon, France, BRON Cedex, France  

Enhancing Traumatic Brain Injury Care Through A Point of Care Precision Medicine Dashboard: Stakeholder-Designed TBI BRIDGE

Author:Halabi, Cathra   Gwiazda, Gina   Miller, Nicolette   Sara, Narender   Etemad, Leila   Martell, Diego   Satris, Gabriela   Manley, Geoffrey   Bove, Riley   

Session Name:P2: Neuro Trauma and Sports Neurology: Epidemiology and Health Care  

Topic:Neuro Trauma and Sports Neurology  

Program Number:P2.007  

Author Institution:University of California, San Francisco, San Francisco, CA  University of California, San Francisco, CA  Medical College of Wisconsin, WI  UCSF Med Ctr/Dept of Neurosurgery, San Francisco, CA  University of California, San Francisco, Berkeley, CA  

Linking Real-world Mobility to Molecular Markers of Neuroaxonal Damage in People With Progressive Multiple Sclerosis

Author:Abdelhak, Ahmed   Joseph, Gabby   Bove, Riley   Cree, Bruce   Block, Valerie   

Session Name:P4: Multiple Sclerosis: Digital Health, Biomarkers, and Artificial Intelligence 1  

Topic:Multiple Sclerosis  

Program Number:P4.002  

Author Institution:UCSF Weill Institute of Neuroscience, San Francisco, CA  UCSF, San Francisco, CA  University of California, San Francisco, Berkeley, CA  UCSF, Multiple Sclerosis Center, San Francisco, CA  University of California, San Francisco, San Francisco, CA  

Efficient, Scalable Generation of a Real-world Clinical MS Cohort Using LLM: Validation and Applications

Author:Poole, Shane   Sisodia, Nikki   Wijangco, Jaeleene   Bove, Riley   

Session Name:P4: Multiple Sclerosis: Digital Health, Biomarkers, and Artificial Intelligence 1  

Topic:Multiple Sclerosis  

Program Number:P4.005  

Author Institution:UCSF, San Francisco, CA  University of California San Francisco, San Francisco, CA  University of California, San Francisco, Berkeley, CA